Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 88pembrolizumab 77Pemetrexed 65Cisplatin 56Paclitaxel 33Docetaxel 31durvalumab 28atezolizumab 28Nivolumab 28Specimen Handling 25Magnetic Resonance Spectroscopy 20Gemcitabine 19osimertinib 18130-nm albumin-bound paclitaxel 18Etoposide 17Radiotherapy 14Cetuximab 14Platinum 12Taxes 11Immunoglobulin G 101,2-diaminocyclohexaneplatinum II citrate 10Radiation 9Ipilimumab 9Disulfides 9Bevacizumab 9amivantamab 8Topotecan 8fludarabine 7Ramucirumab 7Radiosurgery 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ceritinib × Thoracic × 30 days × Clear all
NCT03611738 2026-05-15

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Active not recruiting
21 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡